Patricia Mae G Santos1, Kaitlyn Lapen1, Zhigang Zhang2, Stephanie Lobaugh2, C Jillian Tsai1, T Jonathan Yang1, Justin E Bekelman3, Erin F Gillespie4. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Radiation Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 4. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York; Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: efgillespie@ucsd.edu.
Abstract
PURPOSE: Guidelines recommend short-course (≤10 fractions) external-beam radiation therapy (EBRT) for bone metastases. Stereotactic body radiation therapy (SBRT) may also improve outcomes; however, routine use is not recommended outside clinical trials. We assessed national radiation therapy trends in complex techniques for bone metastases and associated expenditures. METHODS AND MATERIALS: Using a claims-based Medicare data set covering 84% of beneficiaries, we assessed the relative proportion of all radiation episodes represented by bone metastases. We then evaluated use of short-course and long-course (>10 fractions) EBRT, intensity modulated radiation therapy (IMRT), and SBRT for bone metastases in hospital-affiliated outpatient (OPD) or freestanding (FREE) facilities. We assessed differences using χ2d or Wilcoxon rank sum tests for categorical and continuous variables, respectively. We identified associations with modality, fractionation, and expenditures using multivariable logistic/linear regression. RESULTS: Among 467,781 radiation episodes for 17 cancer diagnoses, the overall proportion of episodes dedicated to bone metastases (9.4%) was stable from 2015 to 2017, although treatments were increasing in the hospital-affiliated outpatient setting (P < .005). We identified 40,993 episodes for bone metastases, of which 63% were short-course EBRT, 24% were long-course EBRT, 7% were SBRT, and 6% were IMRT. Techniques more common in the hospital-affiliated outpatient setting included short-course EBRT (OPD, 69%, vs FREE, 56%) and SBRT (OPD, 9%, vs FREE, 5%). Techniques more common among free-standing centers included long-course EBRT (OPD, 19%, vs FREE, 31%) and IMRT (OPD, 4%, vs FREE, 9%). From 2015 to 2017, long-course EBRT decreased by an absolute 8%; short-course EBRT, SBRT, and IMRT increased by 4%, 2.5%, and 1%, respectively. The SBRT/IMRT uptake did not differ by setting (P = .4). Differences in expenditures between SBRT and short-course EBRT decreased by a relative 8% in professional and 12% in technical fees. CONCLUSIONS: Approximately 1 in 4 patients received long-course EBRT, with small reductions in use largely replaced by complex treatment modalities. However, expenditures for complex modalities also decreased over time. As alternative payment models take effect, quality metrics are needed to ensure appropriate, effective, and safe delivery of complex technologies.
PURPOSE: Guidelines recommend short-course (≤10 fractions) external-beam radiation therapy (EBRT) for bone metastases. Stereotactic body radiation therapy (SBRT) may also improve outcomes; however, routine use is not recommended outside clinical trials. We assessed national radiation therapy trends in complex techniques for bone metastases and associated expenditures. METHODS AND MATERIALS: Using a claims-based Medicare data set covering 84% of beneficiaries, we assessed the relative proportion of all radiation episodes represented by bone metastases. We then evaluated use of short-course and long-course (>10 fractions) EBRT, intensity modulated radiation therapy (IMRT), and SBRT for bone metastases in hospital-affiliated outpatient (OPD) or freestanding (FREE) facilities. We assessed differences using χ2d or Wilcoxon rank sum tests for categorical and continuous variables, respectively. We identified associations with modality, fractionation, and expenditures using multivariable logistic/linear regression. RESULTS: Among 467,781 radiation episodes for 17 cancer diagnoses, the overall proportion of episodes dedicated to bone metastases (9.4%) was stable from 2015 to 2017, although treatments were increasing in the hospital-affiliated outpatient setting (P < .005). We identified 40,993 episodes for bone metastases, of which 63% were short-course EBRT, 24% were long-course EBRT, 7% were SBRT, and 6% were IMRT. Techniques more common in the hospital-affiliated outpatient setting included short-course EBRT (OPD, 69%, vs FREE, 56%) and SBRT (OPD, 9%, vs FREE, 5%). Techniques more common among free-standing centers included long-course EBRT (OPD, 19%, vs FREE, 31%) and IMRT (OPD, 4%, vs FREE, 9%). From 2015 to 2017, long-course EBRT decreased by an absolute 8%; short-course EBRT, SBRT, and IMRT increased by 4%, 2.5%, and 1%, respectively. The SBRT/IMRT uptake did not differ by setting (P = .4). Differences in expenditures between SBRT and short-course EBRT decreased by a relative 8% in professional and 12% in technical fees. CONCLUSIONS: Approximately 1 in 4 patients received long-course EBRT, with small reductions in use largely replaced by complex treatment modalities. However, expenditures for complex modalities also decreased over time. As alternative payment models take effect, quality metrics are needed to ensure appropriate, effective, and safe delivery of complex technologies.
Authors: Carol Hahn; Brian Kavanagh; Ajay Bhatnagar; Geraldine Jacobson; Stephen Lutz; Caroline Patton; Louis Potters; Michael Steinberg Journal: Pract Radiat Oncol Date: 2014 Nov-Dec
Authors: Beant S Gill; Sushil Beriwal; Malolan S Rajagopalan; Hong Wang; Kimberly Hodges; Joel S Greenberger Journal: Pract Radiat Oncol Date: 2014-11-05
Authors: Arjun Gupta; Peiqi Wang; Ramy Sedhom; Fumiko Chino; Mark R Waddle; Robert C Miller; David H Johnson; Nina N Sanford; Amol Narang; Sara R Alcorn; Martin A Makary Journal: JCO Oncol Pract Date: 2020-04-13
Authors: Quynh-Nhu Nguyen; Stephen G Chun; Edward Chow; Ritsuko Komaki; Zhongxing Liao; Rensi Zacharia; Bill K Szeto; James W Welsh; Stephen M Hahn; C David Fuller; Bryan S Moon; Justin E Bird; Robert Satcher; Patrick P Lin; Melenda Jeter; Michael S O'Reilly; Valerae O Lewis Journal: JAMA Oncol Date: 2019-06-01 Impact factor: 31.777
Authors: Katie L Spencer; Joanne M van der Velden; Erin Wong; Enrica Seravalli; Arjun Sahgal; Edward Chow; Jorrit-Jan Verlaan; Helena M Verkooijen; Yvette M van der Linden Journal: J Natl Cancer Inst Date: 2019-10-01 Impact factor: 13.506
Authors: Paul M Cheon; Erin Wong; Nemica Thavarajah; Kristopher Dennis; Stephen Lutz; Liang Zeng; Edward Chow Journal: J Bone Oncol Date: 2015-01-23 Impact factor: 4.072
Authors: Ryan Phillips; William Yue Shi; Matthew Deek; Noura Radwan; Su Jin Lim; Emmanuel S Antonarakis; Steven P Rowe; Ashley E Ross; Michael A Gorin; Curtiland Deville; Stephen C Greco; Hailun Wang; Samuel R Denmeade; Channing J Paller; Shirl Dipasquale; Theodore L DeWeese; Daniel Y Song; Hao Wang; Michael A Carducci; Kenneth J Pienta; Martin G Pomper; Adam P Dicker; Mario A Eisenberger; Ash A Alizadeh; Maximilian Diehn; Phuoc T Tran Journal: JAMA Oncol Date: 2020-05-01 Impact factor: 31.777
Authors: Patricia Mae G Santos; Noah J Mathis; Kaitlyn Lapen; Stephanie Lobaugh; Divya Yerramilli; Justin E Bekelman; Erin F Gillespie Journal: JAMA Health Forum Date: 2022-01-14
Authors: Erin F Gillespie; Noah J Mathis; Max Vaynrub; Ernesto Santos Martin; Rupesh Kotecha; Joseph Panoff; Andrew L Salner; Alyson F McIntosh; Ranju Gupta; Amitabh Gulati; Divya Yerramilli; Amy J Xu; Meredith Bartelstein; David M Guttmann; Yoshiya J Yamada; Diana Lin; Kaitlyn Lapen; Deborah Korenstein; David G Pfister; Allison Lipitz-Snyderman; Jonathan T Yang Journal: Clin Transl Radiat Oncol Date: 2022-04-26
Authors: Benjamin A Y Cher; Michael Dykstra; Chang Wang; Matthew Schipper; James A Hayman; Charles S Mayo; Reshma Jagsi Journal: Adv Radiat Oncol Date: 2022-07-22